ARQT - Arcutis Biotherapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARQT is currently covered by 11 analysts with an average price target of $30.74. This is a potential upside of $15.5 (101.71%) from yesterday's end of day stock price of $15.24.

Arcutis Biotherapeutics 's activity chart (see below) currently has 52 price targets and 80 ratings on display. The stock rating distribution of ARQT is 86.36% BUY and 13.64% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.38% with an average time for these price targets to be met of 64.6 days.

Highest price target for ARQT is $21, Lowest price target is $15, average price target is $18.63.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 09-Apr-2025. First documented stock forecast 25-Feb-2020.

Currently out of the existing stock ratings of ARQT, 38 are a BUY (86.36%), 6 are a HOLD (13.64%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$20

$5.39 (36.89%)

$20

24 days ago
(09-Apr-2025)

3/19 (15.79%)

$5.43 (37.27%)

275

Buy

$19

$4.39 (30.05%)

$19

1 months ago
(03-Apr-2025)

0/4 (0%)

$2.84 (17.57%)

Buy

1 months ago
(03-Apr-2025)

1/1 (100%)

$9.67 (36.73%)

27

Hold

$15

$0.39 (2.67%)

$11

2 months 6 days ago
(27-Feb-2025)

3/5 (60%)

$2.2 (17.19%)

41

Buy

$21

$6.39 (43.74%)

$20

2 months 7 days ago
(26-Feb-2025)

3/17 (17.65%)

$8.8 (72.13%)

273

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARQT (Arcutis Biotherapeutics ) average time for price targets to be met?

On average it took 64.6 days on average for the stock forecasts to be realized with a an average price target met ratio 24.38

Which analyst has the current highest performing score on ARQT (Arcutis Biotherapeutics ) with a proven track record?

GRAIG SUVANNAVEJH

Which analyst has the most public recommendations on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh works at MIZUHO and has 7 price targets and 4 ratings on ARQT

Which analyst is the currently most bullish on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh with highest potential upside - $36.28

Which analyst is the currently most reserved on ARQT (Arcutis Biotherapeutics )?

Chris Shibutani with lowest potential downside - -$8.61

Arcutis Biotherapeutics  in the News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?